{"analyses":[{"ciLowerLimit":"0.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.60","groupDescription":"Log-rank test was stratified by randomization stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00003","paramType":"Hazard Ratio (HR)","paramValue":"0.37","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.0","upperLimit":"73.6","value":"63.1"},{"groupId":"OG001","lowerLimit":"20.0","upperLimit":"42.4","value":"30.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"description":"Event-free rate estimated at 12 months for GRFS, which is defined as time from alloHCT to death from any cause, relapse, the first onset of grade 3 or 4 acute GVHD (graded per Mount Sinai aGVHD International Consortium \\[MAGIC\\] criteria), or the first onset of moderate or severe cGVHD (graded per NIH consensus criteria), whichever is earliest, within 2 years from day 0 as assessed by independent EAC.\n\nEach participant in the study is followed for up to 730 days after transplant. The analysis was triggered by the 56th cGFS event (ie, when 56 participants had died or had moderate or severe cGVHD) and not based on duration of follow-up. Therefore, analysis was conducted using all available data at the time that the 56th cGFS event occurred, and event-free rate of GRFS at 12 months was estimated regardless of length of follow-up for individual participants. At time of analysis, not all participants have reached 730 days of follow-up because they enrolled at different times.","dispersionType":"95% Confidence Interval","groups":[{"description":"Orca-T administered after myeloablative conditioning followed by single-agent tacrolimus","id":"OG000","title":"Orca-T"},{"description":"Unmanipulated allograft from peripheral blood of a matched donor after myeloablative conditioning followed by tacrolimus and methotrexate","id":"OG001","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"Day 0 through 730 days after transplantation","title":"Event-free Rate at 12 Months for Graft-versus-host Disease-free and Relapse-free Survival (GRFS) Per EAC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}